recent publications

• academic article

  • Blankenship, J. C., Haldis, T., Feit, F., Hu, T. F., Kleiman, N. S., Topol, E. J., Lincoff, A. M., Investigators, Replace- Angiographic adverse events, creatine kinase-mb elevation, and ischemic end points complicating percutaneous coronary intervention (a replace-2 substudy) American Journal of Cardiology  2006 97:1591-1596  DOI:10.1016/j.amjcard.2005.12.050  PMID:16728220
  • Rajagopal, V., Lincoff, A. M., Cohen, D. J., Gurm, H. S., Hu, T. F., Desmet, W. J., Kleiman, N. S., Bittl, J. A., Feit, F., Topol, E. J. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: An analysis from the randomized evaluation in pci linking angiomax to reduced clinical events (replace-2) trial American Heart Journal  2006 152:149-154  DOI:10.1016/j.ahj.2005.09.007  PMID:16824845
  • Exaire, J. E., Butman, S. M., Ebrahimi, R., Kleiman, N. S., Harrington, R. A., Schweiger, M. J., Bittl, J. A., Wolski, K., Topol, E. J., Lincoff, A. M., Invest, Replace- Provisional glycoprotein iib/iiia blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein iib/iiia inhibition during percutaneous coronary intervention: Predictors and outcome in the randomized evaluation in percutaneous coronary intervention linking angiomax to reduced clinical events (replace)-2 trial American Heart Journal  2006 152:157-162  DOI:10.1016/j.ahj.2005.09.004  PMID:16824849
  • Mahaffey, K. W., Roe, M. T., Kilaru, R., French, J. K., Alexander, J. H., Berdan, L. G., Van De Werf, F., Simoons, M. L., Weaver, W. D., White, H. D., Lincoff, A. M., Kleiman, N. S., et al. Characterization of myocardial infarction as an end point in two large trials of acute coronary syndromes American Journal of Cardiology  2005 95:1404-1408  DOI:10.1016/j.amjcard.2005.02.005  PMID:15950560
  • Quinn, M. J., Aronow, H. D., Calif, R. M., Bhatt, D. L., Sapp, S., Kleiman, N. S., Harrington, R. A., Kong, D. F., Kandzari, D. E., Topol, E. J. Aspirin dose and six-month outcome after an acute coronary syndrome Journal of the American College of Cardiology  2004 43:972-978  DOI:10.1016/j.jacc.2003.09.059  PMID:15028352
  • Lincoff, A. M., Bittl, J. A., Kleiman, N. S., Sarembock, I. J., Jackman, J. D., Mehta, S., Tannenbaum, M. A., Niederman, A. L., Bachinsky, W. B., Tift-Mann, J., Parker, H. G., Kereiakes, D. J., et al. Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the randomized evaluation of pci linking angiomax to reduced clinical events replace -1 trial) American Journal of Cardiology  2004 93:1092-1096  DOI:10.1016/j.amjcard.2004.01.033  PMID:15110198
  • Gurm, H. S., Lincoff, A. M., Kleiman, N. S., Kereiakes, D. J., Tcheng, J. E., Aronow, H. D., Askari, A. T., Brennan, D. M., Topol, E. J. Double jeopardy of renal insufficiency and anemia in patients undergoing percutaneous coronary interventions American Journal of Cardiology  2004 94:30-34  DOI:10.1016/j.amjcard.2004.03.025  PMID:15219504
  • Saw, J., Lincoff, A. M., DeSmet, W., Betriu, A., Rutsch, W., Wilcox, R. G., Kleiman, N. S., Wolski, K., Topol, E. J., Investigators, Replace- Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein iib/iiia blockade compared to heparin with routine glycoprotein iib/iiia blockade - a replace-2 substudy Journal of the American College of Cardiology  2004 44:1194-1199  DOI:10.1016/j.jacc.2004.06.049  PMID:15364319
  • Lincoff, A. M., Kleiman, N. S., Kereiakes, D. J., Feit, F., Bittl, J. A., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D., Ebrahimi, R., Keren, G., Carr, J., et al. Long-term efficacy of bivalirudin and provisional glycoprotein iib/iiia blockade vs heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary revascularization - replace-2 randomized trial JAMA-Journal of the American Medical Association  2004 292:696-703  DOI:10.1001/jama.292.6.696  PMID:15304466
  • Rajagopal, V., Gurm, H. S., Bhatt, D. L., Lincoff, A. M., Tcheng, J. E., Kereiakes, D. J., Kleiman, N. S., Jia, G., Topol, E. J. Relation of an elevated white blood cell count after percutaneous coronary intervention to long-term mortality American Journal of Cardiology  2004 94:190-192  DOI:10.1016/j.amjcard.2004.03.060  PMID:15246898
  • Lincoff, A. M., Bittl, J. A., Harrington, R. A., Feit, F., Kleiman, N. S., Jackman, J. D., Sarembock, I. J., Cohen, D. J., Spriggs, D., Ebrahimi, R., Keren, G., Carr, J., et al. Bivalirudin and provisional glycoprotein iib/iiia blockade compared with heparin and planned glycoprotein iib/iiia blockade during percutaneous coronary intervention - replace-2 randomized trial JAMA-Journal of the American Medical Association  2003 289:853-863  DOI:10.1001/jama.289.7.853  PMID:12588269
  • Gurm, H. S., Bhatt, D. L., Lincoff, A. M., Tcheng, J. E., Kereiakes, D. J., Kleiman, N. S., Jia, G., Topol, E. J. Impact of preprocedural white blood cell count on long term mortality after percutaneous coronary intervention: Insights from the epic, epilog, and epistent trials Heart  2003 89:1200-1204  DOI:10.1136/heart.89.10.1200  PMID:12975419
  • Lincoff, A. M., Kleiman, N. S., Kottke-Marchant, K., Maierson, E. S., Maresh, K., Wolski, K. E., Topol, E. J. Bivalirudin with planned or provisional abciximab versus low-dose heparin and abciximab during percutaneous coronary revascularization: Results of the comparison of abciximab complications with hirulog for ischemic events trial (cachet) American Heart Journal  2002 143:847-853  DOI:10.1067/mhj.2002.122173  PMID:12040347
  • Mazur, W., Kaluza, G. L., Sapp, S., Balog, C., Topol, E. J., Mark, D. B., Ellis, S. G., Kereiakes, D. J., Lincoff, A. M., Kleiman, N. S. Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists American Heart Journal  2002 143:594-601  DOI:10.1067/mhj.2002.121519  PMID:11923795
  • Mahaffey, K. W., Roe, M. T., Dyke, C. K., Newby, L. K., Kleiman, N. S., Connolly, P., Berdan, L. G., Sparapani, R., Lee, K. L., Armstrong, P. W., Topol, E. J., Califf, R. M., et al. Misreporting of myocardial infarction end points: Results of adjudication by a central clinical events committee in the paragon-b trial American Heart Journal  2002 143:242-248  DOI:10.1067/mhj.2002.120145  PMID:11835026
  • Topol, E. J., Lincoff, A. M., Kereiakes, D. J., Kleiman, N. S., Cohen, E. A., Ferguson, J. J., Tcheng, J. E., Sapp, S., Califf, R. M. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization American Journal of Medicine  2002 113:1-6  DOI:10.1016/s0002-9343(02)01145-2  PMID:12106616
  • Rooner, E., Boersma, E., Akkerhuis, K. M., Harrington, R. A., Lincoff, A. M., Deckers, J. W., Karsch, K., Kleiman, N. S., Vahanian, A., Topol, E. J., Califf, R. M., Simoons, M. L. Patients with acute coronary syndromes without persistent st elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein iib/iiia receptor blocker European Heart Journal  2002 23:239-246  DOI:10.1053/euhj.2001.2736  PMID:11792139
  • Roffi, M., Chew, D. P., Mukherjee, D., Bhatt, D. L., White, J. A., Moliterno, D. J., Heeschen, C., Hamm, C. W., Robbins, M. A., Kleiman, N. S., Theroux, P., White, H. D., et al. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes - gradient of benefit related to the revascularization strategy European Heart Journal  2002 23:1441-1448  DOI:10.1053/euhj.2002.3160  PMID:12208224
  • Mahaffey, K. W., Harrington, R. A., Akkerhuis, M., Kleiman, N. S., Berdan, L. G., Crenshaw, B. S., Tardiff, B. E., Granger, C. B., DeJong, I., Bhapkar, M., Widimsky, P., Corbalon, R., et al. Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: Review of the pursuit study Current Controlled Trials in Cardiovascular Medicine  2001 2:187-194  DOI:10.1186/cvm-2-4-187  PMID:11806794  PMCID:PMC57750
  • Aronow, H. D., Topol, E. J., Roe, M. T., Houghtaling, P. L., Wolski, K. E., Lincoff, A. M., Harrington, R. A., Califf, R. M., Ohman, E. M., Kleiman, N. S., Keltai, M., Wilcox, R. G., et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study Lancet  2001 357:1063-1068  DOI:10.1016/s0140-6736(00)04257-4  PMID:11297956
  • Roffi, M., Chew, D. P., Mukherjee, D., Bhatt, D. L., White, J. A., Heeschen, C., Hamm, C. W., Moliterno, D. J., Califf, R. A., White, H. D., Kleiman, N. S., Theroux, P., et al. Platelet glycoprotein iib/iiia inhibitors reduce mortality in diabetic patients with non-st-segment-elevation acute coronary syndromes Circulation  2001 104:2767-2771  DOI:10.1161/hc4801.100029  PMID:11733392
  • Mahaffey, K. W., Harrington, R. A., Akkerhuis, M., Kleiman, N. S., Berdan, L. G., Crenshaw, B. S., Tardiff, B. E., Granger, C. B., DeJong, I., Bhapkar, M., Widimsky, P., Corbalon, R., et al. Systematic adjudication of myocardial infarction end-points in an international clinical trial Current Controlled Trials in Cardiovascular Medicine  2001 2:180-186  DOI:10.1186/cvm-2-4-180  PMID:11806793  PMCID:PMC57749
  • Batchelor, W. B., Granger, C. B., Kleiman, N. S., Phillips, H. R., Ellis, S. G., Betriu, A., Criger, D. A., Stebbins, A. L., Topol, E. J., Califf, R. M., Investigators, Gusto IIb A comparison of ionic versus nonionic contrast medium during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction (gusto iib) American Journal of Cardiology  2000 85:692-697  DOI:10.1016/s0002-9149(99)00842-5  PMID:12000041
  • Cho, L., Topol, E. J., Balog, C., Foody, J. M., Booth, J. E., Cabot, C., Kleiman, N. S., Tcheng, J. E., Califf, R., Lincoff, M. A. Clinical benefit of glycoprotein iib/iiia blockade with abciximab is independent of gender - pooled analysis from epic, epilog and epistent trials Journal of the American College of Cardiology  2000 36:381-386  DOI:10.1016/s0735-1097(00)00746-4  PMID:10933346
  • Topol, C. E., Califf, R. M., Simes, R. J., Van de Werf, F., Diaz, R., Paolasso, E., Aylward, P. E., Keech, A., Klein, W., Piegas, L., Tomov, I., Armstrong, P. W., et al. Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: A randomised trial Lancet  2000 355:337-345  PMID:10665552
  • Kleiman, N. S., Lincoff, A. M., Flaker, G. C., Pieper, K. S., Wilcox, R. G., Berdan, L. G., Lorenz, T. J., Cokkinos, D. V., Simoons, M. L., Boersma, E., Topol, E. J., Califf, R. M., et al. Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes Circulation  2000 101:751-757  PMID:10683348
  • Marso, S. P., Bhatt, D. L., Roe, M. T., Houghtaling, P. L., Labinaz, M., Kleiman, N. S., Dyke, C., Simmoons, M. L., Califf, R. M., Harrington, R. A., Topol, E. J., Investigators, Pursuit Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting Circulation  2000 102:2952-2958  PMID:11113045
  • Kleiman, N. S., Tracy, R. P., Talley, J. D., Sigmon, K., Joseph, D., Topol, E. J., Califf, R. M., Kitt, M., Ohman, E. M. Inhibition of platelet aggregation with a glycoprotein IIb-IIIa antagonist does not prevent thrombin generation in patients undergoing thrombolysis for acute myocardial infarction Journal of Thrombosis and Thrombolysis  2000 9:5-12  DOI:10.1023/a:1018650123272  PMID:10590183
  • Lincoff, A. M., Harrington, R. A., Califf, R. M., Hochman, J. S., Guerci, A. D., Ohman, E. M., Pepine, C. J., Kopecky, S. L., Kleiman, N. S., Pacchiana, C. M., Berdan, L. G., Kitt, M. M., et al. Management of patients with acute coronary syndromes in the united states by platelet glycoprotein iib/iiia inhibition - insights from the platelet glycoprotein iib/iiia in unstable angina: Receptor suppression using integrilin therapy (pursuit) trial Circulation  2000 102:1093-1100  PMID:10973836
  • Braunwald, E., Califf, R. M., Cannon, C. P., Fox, K. A. A., Fuster, V., Gibler, W. B., Harrington, R. A., King, S. B., Kleiman, N. S., Theroux, P., Topol, E. J., Van de Werf, F., et al. Redefining medical treatment in the management of unstable angina American Journal of Medicine  2000 108:41-53  DOI:10.1016/s0002-9343(99)00416-7  PMID:11059440
  • Crenshaw, B. S., Granger, C. B., Birnbaum, Y., Pieper, K. S., Morris, D. C., Kleiman, N. S., Vahanian, A., Califf, R. M., Topol, E. J., Strepto, Gusto- I. Global Utilization Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction Circulation  2000 101:27-32  PMID:10618300
  • McClure, M. W., Berkowitz, S. D., Sparapani, R., Tuttle, R., Kleiman, N. S., Berdan, L. G., Lincoff, A. M., Deckers, J., Diaz, R., Karsch, K. R., Gretler, D., Kitt, M., et al. Clinical significance of thrombocytopenia during a non-st-elevation acute coronary syndrome - the platelet glycoprotein iib iiia in unstable angina: Receptor suppression using integrilin therapy (pursuit) trial experience Circulation  1999 99:2892-2900  PMID:10359733
  • Lincoff, A. M., Califf, R. M., Moliterno, D. J., Ellis, S. G., Ducas, J., Kramer, J. H., Kleiman, N. S., Cohen, E. A., Booth, J. E., Sapp, S. K., Cabot, C. F., Topol, E. J., et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators New England Journal of Medicine  1999 341:319-327  DOI:10.1056/nejm199907293410503  PMID:10423466
  • Kleiman, N. S., Granger, C. B., White, H. D., Armstrong, P., Ardissino, D., Van de Werf, F., Zoldeyhi, P., Thompson, T. D., Califf, R. M., Topol, E. J., Investigators, G. USTO-IIb Death and nonfatal reinfarction within the first 24 hours after presentation with an acute coronary syndrome: Experience from gusto-iib American Heart Journal  1999 137:12-23  DOI:10.1016/s0002-8703(99)70455-2  PMID:9878932
  • Miller, J. M., Smalling, R., Ohman, E. M., Bode, C., Betriu, A., Kleiman, N. S., Schildcrout, J. S., Bastos, E., Topol, E. J., Califf, R. M., GUSTO III Investigators Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the gusto-iii trial) American Journal of Cardiology  1999 84:779-784  DOI:10.1016/s0002-9149(99)00437-3  PMID:10513773
  • Marso, S. P., Lincoff, A. M., Ellis, S. G., Bhatt, D. L., Tanguay, J. F., Kleiman, N. S., Hammoud, T., Booth, J. E., Sapp, S. K., Topol, E. J., Investigators, Epistent Optimizing the percutaneous interventional outcomes for patients with diabetes mellitus - results of the epistent (evaluation of platelet iib/iiia inhibitor for stenting trial) diabetic substudy Circulation  1999 100:2477-2484  PMID:10604884
  • Lincoff, A. M., Tcheng, J. E., Califf, R. M., Kereiakes, D. J., Kelly, T. A., Timmis, G. C., Kleiman, N. S., Booth, J. E., Balog, C., Cabot, C. F., Anderson, K. M., Weisman, H. F., et al. Sustained suppression of ischemic complications of coronary intervention by platelet gp iib/iiia blockade with abciximab - one-year outcome in the epilog trial Circulation  1999 99:1951-1958  PMID:10208997
  • Brieger, D. B., Mak, K. H., White, H. D., Kleiman, N. S., Miller, D. P., Vahanian, A., Ross, A. M., Califf, R. M., Topol, E. J., Investigators, Gusto- I. Benefit of early sustained reperfusion in patients with prior myocardial infarction (the gusto-i trial) American Journal of Cardiology  1998 81:282-287  DOI:10.1016/s0002-9149(97)00909-0  PMID:9468068
  • Kleiman, N. S., Lincoff, A. M., Kereiakes, D. J., Miller, D. P., Aguirre, F. V., Anderson, K. M., Weisman, H. F., Califf, R. M., Topol, E. J., Investigators, Epilog Diabetes mellitus, glycoprotein iib/iiia blockade, and heparin - evidence for a complex interaction in a multicenter trial Circulation  1998 97:1912-1920  PMID:9609084
  • Khan, M. M., Ellis, S. G., Aguirre, F. V., Weisman, H. F., Wildermann, N. M., Califf, R. M., Topol, E. J., Kleiman, N. S., Invest, Epic Does intracoronary thrombus influence the outcome of high risk percutaneous transluminal coronary angioplasty? Clinical and angiographic outcomes in a large multicenter trial Journal of the American College of Cardiology  1998 31:31-36  DOI:10.1016/s0735-1097(97)00423-3  PMID:9426014
  • Califf, R. M., Abdelmeguid, A. E., Kuntz, R. E., Popma, J. J., Davidson, C. J., Cohen, E. A., Kleiman, N. S., Mahaffey, K. W., Topol, E. J., Pepine, C. J., Lipicky, R. J., Granger, C. B., et al. Myonecrosis after revascularization procedures Journal of the American College of Cardiology  1998 31:241-251  DOI:10.1016/s0735-1097(97)00506-8  PMID:9462562
  • Kereiakes, D. J., Kleiman, N. S., Ferguson, J. J., Masud, Z., Broderick, T. M., Abbottsmith, C. W., Runyon, J. P., Anderson, L. C., Anders, R. J., Dreiling, R. J., Hantsbarger, G. L., Bryzinski, B., et al. Pharmacodynamic efficacy, clinical safety, and outcomes after prolonged platelet glycoprotein iib/iiia receptor blockade with oral xemilofiban - results of a multicenter, placebo-controlled, randomized trial Circulation  1998 98:1268-1278  PMID:9751674
  • Ghaffari, S., Kereiakes, D. J., Lincoff, A. M., Kelly, T. A., Timmis, G. C., Kleiman, N. S., Ferguson, J. J., Miller, D. P., Califf, R. A., Topol, E. J., Investigators, Epilog Platelet glycoprotein iib/iia receptor blockade with abciximab reduces ischemic complications in patients undergoing directional coronary atherectomy American Journal of Cardiology  1998 82:7-12  DOI:10.1016/s0002-9149(98)00238-0  PMID:9671000
  • Topol, E. J., Lincoff, A. M., Califf, R. M., Tcheng, J. E., Kleiman, N. S., Adelman, A. G., Burton, J. R., Talley, J. D., Ivanhoe, R. J., Ducas, C., Cheung, P. K., Schick, U., et al. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade Lancet  1998 352:87-92  DOI:10.1016/s0140-6736(98)85010-1  PMID:9672272
  • Ellis, S. G., Lincoff, A. M., Miller, D., Tcheng, J. E., Kleiman, N. S., Kereiakes, D., Califf, R., Topol, E. J., Investigators, Epilog, Investigators, Epic Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology Journal of the American College of Cardiology  1998 32:1619-1623  DOI:10.1016/s0735-1097(98)00403-3  PMID:9822087
  • Ohman, E. M., Kleiman, N. S., Gacioch, G., Worley, S. J., Navetta, F. I., Talley, J. D., Anderson, H. V., Ellis, S. G., Cohen, M. D., Spriggs, D., Miller, M., Kereiakes, D., et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein iib/iiia integrin receptor blockade with integrin in acute myocardial infarction - results of a randomized, placebo-controlled, dose-ranging trial Circulation  1997 95:846-854  PMID:9054741
  • Lincoff, A. M., Califf, R. M., Anderson, K. M., Weisman, H. F., Aguirre, F. V., Kleiman, N. S., Harrington, R. A., Topol, E. J. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein iib/iiia receptor blockade by abciximab (c7e3 fab) among patients with unstable angina undergoing percutaneous coronary revascularization Journal of the American College of Cardiology  1997 30:149-156  PMID:9207636
  • Topol, E. J., Ferguson, J. J., Weisman, H. F., Tcheng, J. E., Ellis, S. G., Kleiman, N. S., Ivanhoe, R. J., Wang, A. L., Miller, D. P., Anderson, K. M., Califf, R. M. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta(3) blockade with percutaneous coronary intervention JAMA-Journal of the American Medical Association  1997 278:479-484  DOI:10.1001/jama.278.6.479  PMID:9256222
  • Topol, E. J., Califf, R. M., Lincoff, A. M., Tcheng, J. E., Cabot, C. F., Weisman, H. F., Kereiakes, D., Lausten, D., Runyon, J. P., Howard, W., Kelly, T., Muncy, D., et al. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization New England Journal of Medicine  1997 336:1689-1696  PMID:9182212
  • Tcheng, J. E., Lincoff, A. M., Sigmon, K. N., Lee, K. L., Kitt, M. M., Califf, R. M., Topol, E. J., Juran, N., Worley, S., Tuzi, J., Hollywood, L., Kleiman, N. S., et al. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT II Lancet  1997 349:1422-1428  PMID:9164315
  • Lincoff, A. M., Tcheng, J. E., Califf, R. M., Bass, T., Popma, J. J., Teirstein, P. S., Kleiman, N. S., Hattel, L. J., Anderson, H. V., Ferguson, J. J., Cabot, C. F., Anderson, K. M., et al. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein iib/iiia receptor antibody fragment abciximab (c7e3 fab) during percutaneous coronary revascularization American Journal of Cardiology  1997 79:286-291  PMID:9036746
  • White, H. D., Barbash, G. I., Califf, R. M., Simes, R. J., Granger, C. B., Weaver, W. D., Kleiman, N. S., Aylward, P. E., Gore, J. M., Vahanian, A., Lee, K. L., Ross, A. M., et al. Age and outcome with contemporary thrombolytic therapy - results from the gusto-i trial Circulation  1996 94:1826-1833  PMID:8873656
  • Ohman, E. M., Armstrong, P. W., Christenson, R. H., Granger, C. B., Katus, H. A., Hamm, C. W., Ohanesian, M. A., Wagner, G. S., Kleiman, N. S., Harrell, F. E., Califf, R. M., Topol, E. J. Cardiac troponin t levels for risk stratification in acute myocardial ischemia New England Journal of Medicine  1996 335:1333-1341  DOI:10.1056/nejm199610313351801  PMID:8857016
  • Aguirre, F. V., Topol, E. J., Anderson, K. M., Kleiman, N. S., Weisman, H. E., FitzPatrick, S. E., Califf, R. M. Clinical benefit within patient subgroups receiving c7e3 fab (abciximab) during percutaneous coronary revascularization: Subgroup analysis from the epic trial Journal of Invasive Cardiology  1996 8:B21-B29
  • Labinaz, M., Sketch, M. H., Stebbins, A. L., DeFranco, A. C., Holmes, D. R., Kleiman, N. S., Betriu, A., Rutsch, W. R., Vahanian, A., Topol, E. J., Califf, R. M. Thrombolytic therapy for patients with prior percutaneous transluminal coronary angioplasty and subsequent acute myocardial infarction American Journal of Cardiology  1996 78:1338-1344  DOI:10.1016/s0002-9149(96)00654-6  PMID:8970403
  • Holmes, D. R., Bates, E. R., Kleiman, N. S., Sadowski, Z., Horgan, J. H. S., Morris, D. C., Califf, R. M., Berger, P. B., Topol, E. J. Contemporary reperfusion therapy for cardiogenic-shock - the gusto-i trial experience Journal of the American College of Cardiology  1995 26:668-674  DOI:10.1016/0735-1097(95)00215-p  PMID:7642857
  • Harrington, R. A., Kleiman, N. S., Kottkemarchant, K., Lincoff, A. M., Tcheng, J. E., Sigmon, K. N., Joseph, D., Rios, G., Trainor, K., Rose, D., Greenberg, C. S., Kitt, M. M., et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein iib/iiia inhibitor during percutaneous coronary intervention American Journal of Cardiology  1995 76:1222-1227  DOI:10.1016/s0002-9149(99)80345-2  PMID:7503000
  • Tcheng, J. E., Harrington, R. A., Kottkemarchant, K., Kleiman, N. S., Ellis, S. G., Kereiakes, D. J., Mick, M. J., Navetta, F. I., Smith, J. E., Worley, S. J., Miller, J. A., Joseph, D. M., et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein iib/iiia blocker integrelin in elective coronary intervention Circulation  1995 91:2151-2157  PMID:7697843
  • Kleiman, N. S., White, H. D., Ohman, E. M., Ross, A. M., Woodlief, L. H., Califf, R. M., Holmes, D. R., Bates, E., Pfisterer, M., Vahanian, A., Topol, E. J. Mortality within 24 hours of thrombolysis for myocardial-infarction - the importance of early reperfusion Circulation  1994 90:2658-2665  PMID:7994805
  • Tcheng, J. E., Ellis, S. G., George, B. S., Kereiakes, D. J., Kleiman, N. S., Talley, J. D., Wang, A. L., Weisman, H. F., Califf, R. M., Topol, E. J. Pharmacodynamics of chimeric glycoprotein iib/iiia integrin antiplatelet antibody fab 7e3 in high-risk coronary angioplasty Circulation  1994 90:1757-1764  PMID:7923659
  • Topol, E. J., Fuster, V., Harrington, R. A., Califf, R. M., Kleiman, N. S., Kereiakes, D. J., Cohen, M., Chapekis, A., Gold, H. K., Tannenbaum, M. A., Rao, A. K., Debowey, D., et al. Recombinant hirudin for unstable angina-pectoris - a multicenter, randomized angiographic trial Circulation  1994 89:1557-1566  PMID:8149521
  • Williams, D. O., Topol, E. J., Califf, R. M., Roberts, R., Mancini, G. B. J., Joelson, J. M., Ellis, S. G., Kleiman, N. S. Intravenous recombinant tissue-type plasminogen-activator in patients with unstable angina-pectoris - results of a placebo-controlled, randomized trial Circulation  1990 82:376-383  PMID:2115407